Current:Home > InvestThe FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients. -Wealth Momentum Network
The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.
View
Date:2025-04-17 11:14:49
Ahead of a key meeting Tuesday to weigh the potential approval of midomafetamine, or MDMA, for patients with post-traumatic stress disorder, the Food and Drug Administration is proposing a new set of restrictions on how eligible patients would be able to get the drug.
Details of the FDA's proposal were published Friday in a set of documents released by the agency ahead of an advisory committee meeting next week.
After the panel votes, drugmaker Lykos Therapeutics says the FDA is expected to make a decision by Aug. 11 on whether to approve its approach for patients with PTSD: a four-month course of MDMA combined with psychotherapy.
Among the FDA's questions for the committee is whether the benefits of MDMA, combined with the FDA's proposed restrictions on prescriptions for the hallucinogenic drug, will be enough to outweigh its risks.
"Patient impairment is an expected effect from midomafetamine administration and there must be safeguards to mitigate serious harm from patient impairment, similar to the risk mitigation in the clinical trials, to support patient safety," the FDA's reviewers said in a briefing document ahead of the meeting.
Under the proposal, administering MDMA would be restricted to healthcare facilities that agree to ensure at least two providers are onsite to monitor patients while taking the drug.
Patients will need to be monitored for at least eight hours, until they are psychologically stable enough to be discharged to an adult after the session. During the trials, many ended up staying overnight at study sites, being monitored by therapists.
Providers will also need to prepare for some physical risks. In the trials, one participant was hospitalized after MDMA was suspected to have exacerbated a pre-existing heart problem.
Patients will also need to be enrolled in a registry tracking side effects and issues that come up from the sessions, as well as how they are faring following completion of the treatment.
"We are also concerned about worsening of psychological disorders that cause disability or that may lead to hospitalization or death, and suicidal behaviors and ideation," the FDA said.
The drugmaker has also been in talks with the FDA over other steps to curb risks of the drug, like providing the product in only single dose packages aimed at limiting the risk of "nonmedical use," Lykos said in their briefing document.
The FDA often turns to its authority to apply additional restrictions on prescription drugs, dubbed Risk Evaluation and Mitigation Strategies or REMS, to curb the pitfalls of drugs that it thinks would otherwise be too dangerous to approve.
Nasal sprays of hallucinogen esketamine to treat depression, branded as Spravato, were also approved in 2019 under these kinds of REMS restrictions.
Additional restrictions could be imposed by a different agency – the Drug Enforcement Administration – which will be responsible for "rescheduling" the drug.
The DEA currently deems MDMA or "ecstasy" to be a Schedule I drug, alongside other substances like heroin which the DEA says have "no currently accepted medical use and a high potential for abuse."
Alexander TinAlexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19.
TwitterveryGood! (3)
Related
- Can Bill Belichick turn North Carolina into a winner? At 72, he's chasing one last high
- Chicago to extend migrant shelter stay limits over concerns about long-term housing, employment
- Ford, Tesla, Jaguar among nearly 2.2 million vehicles recalled: Check car recalls here
- Heart and Cheap Trick team up for Royal Flush concert tour: 'Can't wait'
- Romantasy reigns on spicy BookTok: Recommendations from the internet’s favorite genre
- Horoscopes Today, January 29, 2024
- With police stops in the spotlight, NYC council is expected to override mayor on transparency bill
- Priceless painting stolen by New Jersey mobsters in 1969 is found and returned to owner's 96-year-old son
- Meta donates $1 million to Trump’s inauguration fund
- Israel military operation destroys a Gaza cemetery. Israel says Hamas used the site to hide a tunnel
Ranking
- $73.5M beach replenishment project starts in January at Jersey Shore
- Olivia Culpo Celebrates Fiancé Christian McCaffrey After Win Secures Spot in 2024 Super Bowl
- IVF may be tax deductible, but LGTBQ+ couples less likely to get write-offs
- Ex-IRS contractor Charles Littlejohn, who admitted leaking Trump's tax records, sentenced to 5 years in prison
- Rams vs. 49ers highlights: LA wins rainy defensive struggle in key divisional game
- Republican-led Kentucky House passes bill aimed at making paid family leave more accessible
- Taylor Swift attends Kansas City Chiefs, Baltimore Ravens AFC championship game
- Illinois election board to consider whether to boot Trump from ballot over insurrection amendment
Recommendation
US appeals court rejects Nasdaq’s diversity rules for company boards
Real estate giant China Evergrande ordered by Hong Kong court to liquidate
Mango’s Sale Has All the Perfect Capsule Wardrobe Staples You Need up to 70% off Right Now
How a yoga ad caught cyclist Anna Moriah Wilson's killer, Kaitlin Armstrong
'Kraven the Hunter' spoilers! Let's dig into that twisty ending, supervillain reveal
Recalled cinnamon applesauce pouches were never tested for lead, FDA reports
Ukrainian and Hungarian foreign ministers meet but fail to break a diplomatic deadlock
India’s navy rescues second Iranian-flagged fishing boat hijacked by Somali pirates